Press Release
08 |
Apr 2024 |
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Cl... |
05 |
Apr 2024 |
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA... |
21 |
Mar 2024 |
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results... |
14 |
Mar 2024 |
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow... |
11 |
Mar 2024 |
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences... |
20 |
Feb 2024 |
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering... |
20 |
Feb 2024 |
IntelGenx Launches Preferred Share Regulation A Offering... |
05 |
Feb 2024 |
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform... |